Member Info for CityTTrader

7 months ago Exact Sciences paid $2.8bn for a similar but inferior product. Part of that price was because there was already a sales and marketing support network in place for the product. STEM does not have this and so a discount could be expected for this. Except that if the buyer is a major then they will already have such a network. I'm going to stick with a sale of about £2.8bn giving a slight premium because its a 40% superior product. TILS has about 170m shares in circulation which should mean a similar figure for STEM. This gives a valuation of £16.47 per share for STEM.
So we can place a current value on TILS of between £20-30 £20 without any COVID19 treatment £30 with.
It might take a year to reach these prices or it might be quicker but one thing is for sure and that is you don't need to look at another share until this happens. It will be the easiest way you ever made money.

Just been out all day and WOW what a day we've had here!!!

Additionally, Tiziana also reported the successful completion of a Phase 1 trial with oral administration of Foralumab, demonstrating that the treatment was well-tolerated up to a 5 mg dose ( https://www.tizianalifesciences.com/news-item?s=2020-01-09-tiziana-reports-phase-1-clinical-data-demonstrating-oral-treatment-with-foralumab-a-fully-human-anti-cd3-monoclonal-antibody-is-well-tolerated-in-healthy-volunteers ). Importantly, both clinical studies conducted at the Brigham and Women's Hospital and Harvard Medical School, Boston, MA., indicated that the severe toxicities that are commonly associated with intravenous administration of anti-CD3 mAbs were not observed with either oral or nasal administration of Foralumab.

"Nasal administration of Foralumab is a potentially transformative immunomodulatory approach for treating patients with a variety of human diseases. Results from animal studies, conducted in our laboratory have established that nasal administration of anti-CD3 induces regulatory T cells that suppress inflammation and ameliorate diseases in animal models. This scientific advancement provides the basis to move forward with clinical development of nasally administered Foralumab in COVID-19 disease," commented Dr. Weiner, who is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis Center and Co-Director of the Ann Romney Center for Neurologic Diseases at the Brigham & Women's Hospital. He continued, "modulating the immune system with nasal anti-CD3 is a first-in-class immunotherapeutic approach to treat COVID-19 disease."

"Our proprietary immunotherapeutic approach using nasal, inhalation and oral administration of mAbs are novel and promising therapies that stimulate or modulate the immune system so that T regulatory cells (Tregs) are supercharged to inhibit inflammation. The common underlying concept in these alternative delivery approaches is to strengthen one's own body defense to fight against inflammation in these diseases. Being a fully human anti-CD3 mAb, we believe Foralumab is most suitable for immunotherapies, as it does not produce an immune response unlike other humanized anti-CD3 mAbs" commented Dr. Shailubhai, CEO and CSO of Tiziana Life Sciences.

New York/London, July 31, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has submitted a patent application for the potential use of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), for the treatment of COVID-19 either alone or in combination with other anti-viral drugs. Recent clinical studies imply that a combination of anti-inflammatory and anti-viral drugs may be more effective to treat patients at different stages of COVID-19 disease.

-- Nasal administration with Foralumab could potentially modulate or stimulate immune system to suppress cytokine storm and reduce respiratory failure in

COVID-19 patients

-- Nasal administration of Foralumab may be combined with other anti-viral drugs to improve treatment efficacy

Tiziana has a worldwide exclusive license for nasal administration of Foralumab and other anti-CD3 mAbs for the treatment of neurodegenerative and other diseases. The Company previously announced development of a robust formulation and delivery of Foralumab using a nasal spray device and the successful completion of a Phase 1 trial demonstrating that the treatment was well-tolerated and showed positive immunomodulatory effects as measured by biomarker analysis ( https://www.tizianalifesciences.com/news-item?s=2018-11-28-tiziana-announces-initiation-of-phase-1-clinical-trial-with-nasal-administration-of-foralumab-a-fully-human-anti-cluster-definition-3-monoclonal-antibody-anti-cd3-mab-in-healthy-volunteers ).

NM

SK I filled my boots this afternoon. What a gift that was.

$16.79

They announced 3 months ago they were going to delay the move from AIM. All they've done is delay further. The MMs played a blinder and took out all thos stop losses. IG must be laughing all the way to the bank. Bet a few spreadbetters will get home tonight take a look and wet themeslves. Never ever use a stop loss its a guaranted way to lose money.

HAve jumped in this morning. Very difficult to buy. On NT most of thee first 40 minutes.

Tiziana Life Sciences to Participate in Investor Webinar to Provide Corporate Updates and Q&A Session on July 30, 2020

NEW YORK/LONDON, July 30, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced that Kunwar Shailubhai, Ph.D., the Company's CEO and CSO, will share insight into Tiziana's development pipeline and upcoming milestones during an investor webinar, hosted by RedChip Companies, on Thursday, July 30, 2020 at 4:00 p.m. U.S. Eastern. A live Q&A session with Shailubhai will follow the presentation.

To register for the free webinar, please visit: https://www.redchip.com/corporate/webinar_register/68

About the webinair later today

I tend to find that people who raise issues such as placings are derapers looking to buy in cheaply. They clearly have not read the RNS history here.

A Billion is about £5.88 a share

A vaccine protects you from catching something. A treatment treats you once you have it. Large enough market for both products for many years now.

Just sold my entinre holding here then bought it back and gained more shares. NICE ;-)

Why is it that when companies give guidance of 'within 14 days' they always leave it util the very last day!

Which again is after we have voted for the split.

Fabuous video. I'm just so very happy to be in this.

Now that's a word I like to hear.

Looking good to me